11.2013
A Publication of the American Academy of Dermatology Association Navigating Practice, Policy, and Patient Care
www.aad.org
Tomorrow’s teammates? Dermatologists ponder future of care coordination with non-physician clinicians 18
+ 06 Coding 10 Research 13 Legal Issues 16 Practice Management 36 Academy News
in this issue
from the editor
American Academy of Dermatology Association CELEBRATING
YEARS OF EXCELLENCE IN DERMATOLOGY
DEAR READERS,
VOL. 23 NO. 11 | NOVEMBER 2013
You can’t do much better than free.
PRESIDENT
PHYSICIAN EDITOR
Dirk M. Elston, MD
Abby Van Voorhees, MD
PHYSICIAN REVIEWER
e all gripe and groan about the rising costs of everything, from running our businesses to maintaining the homes we live in. I know you’ll find it hard to believe, but there are some of us who complain about the cost of the AAD membership. Rarely do we hear of costs going down. And when they do, like with the housing bubble, it is generally not to our advantage. That is why free stands out. This month we focus on something that the Academy is going to give to us for free. The new patient safety workbook created by the AAD puts in one place the steps that are helpful to facilitate surgical site accreditation. That the process is still a lot of work is unfortunately true, but it sure is nice that some of our fellow dermatologists, working under the umbrella of the Academy, put this workbook together. And did I say that it is free? You’ll be able to download it from the website. What a terrific benefit of our membership! I don’t know about you, but I can afford the cost of the paper! So definitely put this on your to-do list….both for the safety of your patients and to guide your establishment of safe practices. Also this month we write about the increasing presence of non-physician clinicians in dermatology. Clearly one reason for this is that there aren’t enough dermatologists being trained, and this translates into long waiting lists for appointments. A full 40 percent of us now employ these providers, allowing us to handle more patients and help us serve our communities. With the number of physicians static and the number of non-physician clinicians growing, the face of dermatology will continue to change. Learning to be the captain of the dermatology team is going to be critical to the success of our futures. We see in yet another article that there is another change coming too — it’s called clinical integration. Clinical integration means aligning one’s interests with other physicians in the care of patients. Shay and Gosfield advise us to start talking to the various players in our neighborhoods. They say that the key to a successful integration is making sure that you have a unifying vision. This will allow your interests to align with the other providers. Again, we hear that the key step is free: talking and listening. Americans have always liked getting things for free. Land was practically free for much of the 1800s; the frontier did not officially close until 1890. And now free stuff is back once again courtesy of the AAD. So don’t forget to download the workbook, and while you are doing so be sure to say some thanks to the Academy. Hope that this gets you in the mood for the holiday and that you get a chance to relax a bit over the Thanksgiving weekend, enjoying the company of family and other loved ones. Happy Thanksgiving to all. Enjoy your reading.
W
Barbara Mathes, MD EXECUTIVE DIRECTOR
Elaine Weiss, JD DEPUTY EXECUTIVE DIRECTOR
Eileen Murray, CAE PUBLISHER
Lara Lowery EDITOR
Katie Domanowski MANAGING EDITOR
Richard Nelson ASSISTANT EDITOR
John Carruthers DESIGN MANAGER
Ed Wantuch EDITORIAL DESIGNER
Theresa Oloier ADVERTISING MANAGER
CONTRIBUTING WRITERS
Diane Donofrio Angelucci Jan Bowers Alice Gosfield, JD Nikki Haton Rose Holcomb Victoria Houghton Alexander Miller, MD Margaret Parsons, MD Daniel Shay, JD Susan Treece EDITORIAL ADVISORS
Lakshi Aldredge, MSN, ANP-BC Jeffrey Benabio, MD Jeffrey Dover, MD Rosalie Elenitsas, MD John Harris, MD, PhD Chad Hivnor, MD Sylvia Hsu, MD Risa Jampel, MD Christopher Miller, MD Christen Mowad, MD Robert Sidbury, MD Ravi Ubriani, MD
Brian Searles ADVERTISING SPECIALIST
Carrie Parratt Printed in U.S.A. Copyright © 2013 by the American Academy of Dermatology Association 930 E. Woodfield Rd. Schaumburg, IL 60173-4729 Phone: (847) 330-0230 Fax: (847) 330-0050 MISSION STATEMENT: Dermatology World is published monthly by the American Academy of Dermatology Association. Through insightful analysis of the trends that affect them, it provides members with a trusted, inside source for balanced news and information about managing their practice, understanding legislative and regulatory issues, and incorporating clinical and research developments into patient care. Dermatology World® (ISSN 10602445) is published monthly by the American Academy of Dermatology and AAD Association, 930 E. Woodfield Rd., Schaumburg, IL 60173-4729. Subscription price $48.00 per year included in AAD membership dues. Non-member annual subscription price $108.00 US or $120.00 international. Periodicals Postage Paid at Schaumburg, IL and additional mailing offices. POSTMASTER: Send address changes to Dermatology World®, American Academy of Dermatology Association, P.O. Box 4014, Schaumburg, IL 60168-4014. ADVERTISING: For display advertising information contact Richard Sieber at (301) 968-3516 or
[email protected].
ABBY S. VAN VOORHEES, MD, PHYSICIAN EDITOR
DERMATOLOGY WORLD // November 2013
1
11.2013
A Publication of the American Academy of Dermatology Association Navigating Practice, Policy, and Patient Care
features
www.aad.org
depts 01
FROM THE EDITOR
06
CRACKING THE CODE
“The Academy is making inroads into a team care approach with 18 dermatologists as captains of the TOMORROW’S TEAMMATES? Dermatologists ponder future of care coordination dermatology care with non-physician clinicians team. If there’s no team built, then 24 what will we be PROVING PATIENT SAFETY Workbook will guide office-based dermatologists captains of?” to better practices, accreditation COVER STORY
BY JOHN CARRUTHERS
BY JAN BOWERS
30
COSMETIC LASER ADVANCES GAIN MOMENTUM
BY DIANE DONOFRIO ANGELUCCI
When modifier 59 is not enough, part two.
08
ROUNDS
Tort reform in the states.
10
ACTA ERUDITORUM
Can skin biopsy reports for adult HenochSchönlein purpura identify patients at risk for renal involvement?
13
LEGALLY SPEAKING
Clinical integration: The key to your future.
16
IN PRACTICE
Building balance.
34
FROM THE PRESIDENT
36
ACADEMY UPDATE
2014 Annual Meeting registration, more.
40
ACCOLADES
44 2013 HOW InHOWse Design Award – Cover/Feature Design
2011, 2012, and 2013 Graphic Design USA Award – Cover/Feature Design
2011 Ozzie Silver Award, Best Redesign: Association/Non-profit
2011 AM&P Excel Bronze Award, Magazine Redesign
2 DERMATOLOGY WORLD // November 2013
FACTS AT YOUR FINGERTIPS
Dermatology World continues to deliver information members need.
www.aad.org/dw
Discover a tazarotene treatment that can help quiet moderate to severe acne.
Don’t let acne have the final word. FABIOR Foam is the only retinoid in a topical foam formulation for acne vulgaris in patients aged 12 years or older. Efficacy in moderate to severe acne vulgaris1 t1BUJFOUTVTJOH'"#*03'PBN / BOEWFIJDMFGPBN /
t4JHOJmDBOUSFEVDUJPOJOJOnBNNBUPSZ '"#*03'PBN WFIJDMFGPBN
OPOJOnBNNBUPSZ
BOEUPUBMMFTJPOT
BUXFFL P GPSBMM
t4JHOJmDBOUMZNPSFQBUJFOUTVTJOH'"#*03'PBN WTWFIJDMFGPBN XFSF iDMFBSwPSiBMNPTUDMFBSwXJUIBUMFBTUBHSBEFJNQSPWFNFOUBUXFFL P
Tolerability demonstrated in pivotal studies for FABIOR Foam t1FSDFOUBHFPGQBUJFOUTXJUIBOZUSFBUNFOUSFMBUFEBEWFSTFSFBDUJPO "3 t*OEJWJEVBMBQQMJDBUJPOTJUF"3TöJSSJUBUJPO
ESZOFTT
FSZUIFNB
FYGPMJBUJPO
QBJO
QIPUPTFOTJUJWJUZ
QSVSJUVT
BOEEFSNBUJUJT
t-PDBMTLJOSFBDUJPOT ESZOFTT FSZUIFNB QFFMJOH CVSOJOHTUJOHJOH BOEJUDIJOH QFBLFE BUXFFLBOEHSBEVBMMZSFEVDFEUIFSFBGUFSXJUIDPOUJOVFEVTFPG'"#*03'PBN t-FTTUIBO PGQBUJFOUTEJTDPOUJOVFEEVFUPMPDBMTLJOSFBDUJPOT t1FSDFOUBHFPGQBUJFOUTXJUITFWFSF"3T Vehicle t"RVFPVTCBTFEGPBNGPSNVMBUJPOUIBUEPFTOPUDPOUBJOQBSBCFOTPSBMDPIPM
(tazarotene) Foam, 0.1% Important Safety Information t FABIOR Foam is contraindicated in pregnancy because tazarotene is a teratogenic substance. FABIOR Foam may cause fetal harm when administered to a pregnant woman. If the patient becomes pregnant while using this drug, treatment should be discontinued and the patient apprised of the potential hazard to the fetus t Females of child-bearing potential should be warned of the potential risk and use adequate birth-control measures to avoid pregnancy. A negative serum or urine result for pregnancy test should be obtained within 2 weeks prior to therapy with FABIOR Foam; therapy should begin during a normal menstrual period t FABIOR Foam should be used with caution in patients with a history of local tolerability reactions or local hypersensitivity. Retinoids should not be used on abraded or eczematous skin, as they may cause severe irritation. Contact with the mouth, eyes, and mucous membranes should be avoided. Weather extremes, such as wind or cold, may be more irritating to patients using FABIOR Foam. Excessive topical application of FABIOR Foam may lead to marked redness, peeling, or discomfort t FABIOR Foam may cause skin redness, peeling, burning, or excessive pruritus. Concomitant topical acne therapy should be used with caution because a cumulative irritant effect may occur. If skin irritation occurs, therapy with FABIOR Foam should be reduced to an interval the patient can tolerate, temporarily interrupted, or discontinued. In addition, concomitant dermatologic medications and cosmetics that have a strong drying effect should be avoided t Because of heightened burning susceptibility, exposure to sunlight (including sunlamps) should be avoided when using FABIOR Foam. Patients must be warned to use sunscreens and protective clothing. Patients with sunburn should be advised not to use FABIOR Foam until fully recovered. Patients who may have considerable sun exposure due to their occupation and those patients with inherent sensitivity to sunlight should exercise particular caution. FABIOR Foam should be used with caution in patients with a personal or family history of skin cancer or if the patient is also taking drugs known to be photosensitizers t The propellant in FABIOR Foam is flammable. Instruct the patient to avoid fire, flame, and/or smoking during and immediately following application t Adverse reactions reported in ≥6% of patients treated with FABIOR Foam vs vehicle foam were application site reactions including irritation (14%, 1%), dryness (7%, 1%), erythema (6%,
